Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto H.

Target Oncol. 2019 Aug;14(4):479-489. doi: 10.1007/s11523-019-00654-4.

PMID:
31301014
2.

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.

Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, Lees J, Zou L, Martuza RL, Wakimoto H, Rabkin SD.

Nat Commun. 2019 Jul 2;10(1):2910. doi: 10.1038/s41467-019-10993-5.

3.

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.

Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RL.

Mol Ther Oncolytics. 2019 Mar 29;13:58-66. doi: 10.1016/j.omto.2019.03.008. eCollection 2019 Jun 28.

4.

Performance of a Hospital Pathway for Patients With a New Single Brain Mass.

Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT.

J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25.

PMID:
30681891
5.

Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-019-0355-0.

PMID:
30670876
6.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.

Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H.

Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2.

7.

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13. Erratum in: Nat Med. 2019 Mar;25(3):529.

8.

Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.

Saha D, Martuza RL, Rabkin SD.

Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.

9.

Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2018 Jul 17;92(15). pii: e00246-18. doi: 10.1128/JVI.00246-18. Print 2018 Aug 1.

10.

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.

Clin Cancer Res. 2018 Jul 15;24(14):3409-3422. doi: 10.1158/1078-0432.CCR-17-1717. Epub 2018 Mar 29.

11.

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.

Saha D, Martuza RL, Rabkin SD.

Oncoscience. 2017 Sep 20;4(7-8):67-69. doi: 10.18632/oncoscience.359. eCollection 2017 Jul. No abstract available.

12.

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Saha D, Martuza RL, Rabkin SD.

Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006.

13.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

14.

Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.

Kim D, Niemierko A, Hwang WL, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2018 Apr;128(4):1123-1132. doi: 10.3171/2016.11.JNS16913. Epub 2017 Jun 16.

PMID:
28621619
15.

Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.

Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.

16.

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.

Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A, Suvà ML.

Nature. 2016 Nov 10;539(7628):309-313. doi: 10.1038/nature20123. Epub 2016 Nov 2.

17.

Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.

Esaki S, Rabkin SD, Martuza RL, Wakimoto H.

Am J Cancer Res. 2016 Jan 15;6(2):300-11. eCollection 2016.

18.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H.

Neuro Oncol. 2016 Sep;18(9):1278-87. doi: 10.1093/neuonc/now031. Epub 2016 Mar 6.

19.

Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.

Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, Barker FG 2nd, Martuza RL, Loeffler JS, Oh KS, Shih HA, Larvie M.

Neuro Oncol. 2016 Jun;18(6):863-72. doi: 10.1093/neuonc/nov285. Epub 2015 Nov 22.

20.

Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.

Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG 2nd, Martuza RL, McGuone D, Oh KS, Loeffler JS, Shih HA.

J Neurosurg. 2016 Jan;124(1):106-14. doi: 10.3171/2015.1.JNS142228. Epub 2015 Aug 14.

PMID:
26274991
21.

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.

Nigim F, Cavanaugh J, Patel AP, Curry WT Jr, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H.

J Neuropathol Exp Neurol. 2015 Jul;74(7):710-22. doi: 10.1097/NEN.0000000000000210.

22.

Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.

Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H.

J Neurooncol. 2015 Jan;121(1):91-100. doi: 10.1007/s11060-014-1612-1. Epub 2014 Sep 12.

23.

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE.

Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. Epub 2014 Jun 12.

24.

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.

Cell. 2014 Apr 24;157(3):580-94. doi: 10.1016/j.cell.2014.02.030. Epub 2014 Apr 10.

25.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

26.

Vestibular schwannoma: suboccipital approach.

Sheth SA, Tirino JL, Martuza RL.

Neurosurg Focus. 2014 Jan;36(1 Suppl):1. doi: 10.3171/2014.V1.FOCUS13318.

PMID:
24380512
27.

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11. doi: 10.1073/pnas.1307935110. Epub 2013 Jun 10.

28.

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.

29.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.

Cell Rep. 2013 May 30;3(5):1567-79. doi: 10.1016/j.celrep.2013.04.021. Epub 2013 May 23.

30.

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.

Stem Cells Transl Med. 2012 Apr;1(4):322-32. doi: 10.5966/sctm.2011-0035. Epub 2012 Mar 21.

31.

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2013 Jan;20(1):17-24. doi: 10.1038/cgt.2012.75. Epub 2012 Nov 9.

32.

Postoperative imaging of vestibular schwannomas.

Ginat DT, Martuza RL.

Neurosurg Focus. 2012 Sep;33(3):E18. doi: 10.3171/2012.6.FOCUS12150. Review.

PMID:
22937852
33.

Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report.

Peterfreund RA, Luman E, Martuza RL.

Case Rep Pulmonol. 2012;2012:804789. doi: 10.1155/2012/804789. Epub 2012 Jul 29.

34.

Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.

Mol Ther. 2013 Jan;21(1):68-77. doi: 10.1038/mt.2012.175. Epub 2012 Aug 28.

35.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

36.

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2012 Apr;86(8):4420-31. doi: 10.1128/JVI.00017-12. Epub 2012 Feb 15.

37.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

38.

Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.

Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD.

Neuro Oncol. 2012 Feb;14(2):132-44. doi: 10.1093/neuonc/nor195. Epub 2011 Nov 7.

39.

Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL.

Clin Cancer Res. 2011 Dec 1;17(23):7383-93. doi: 10.1158/1078-0432.CCR-11-1762. Epub 2011 Oct 5.

40.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

41.

Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.

Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G.

Clin Cancer Res. 2011 Jul 1;17(13):4484-93. doi: 10.1158/1078-0432.CCR-11-0575. Epub 2011 May 10.

42.

A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.

Kanai R, Wakimoto H, Martuza RL, Rabkin SD.

Clin Cancer Res. 2011 Jun 1;17(11):3686-96. doi: 10.1158/1078-0432.CCR-10-3142. Epub 2011 Apr 19.

43.

Identification of diagnostic serum protein profiles of glioblastoma patients.

Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A.

J Neurooncol. 2011 Mar;102(1):71-80. doi: 10.1007/s11060-010-0284-8. Epub 2010 Jul 9.

44.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL.

Cancer Res. 2010 May 15;70(10):3890-5. doi: 10.1158/0008-5472.CAN-10-0155. Epub 2010 Apr 27.

45.

Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL.

Gene Ther. 2010 Jun;17(6):805-10. doi: 10.1038/gt.2010.20. Epub 2010 Mar 11.

46.

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL.

Gene Ther. 2009 Dec;16(12):1477-82. doi: 10.1038/gt.2009.94.

47.

Genetic determinants of hearing loss associated with vestibular schwannomas.

Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB Jr, Stemmer-Rachamimov AO.

Otol Neurotol. 2009 Aug;30(5):661-7. doi: 10.1097/MAO.0b013e3181a66ece.

PMID:
19546833
48.

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.

Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886. Epub 2009 Apr 7.

49.

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7. doi: 10.1073/pnas.0806647106. Epub 2009 Mar 5.

50.

Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.

Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2009 Jul;16(7):551-60. doi: 10.1038/cgt.2009.10. Epub 2009 Feb 6.

Supplemental Content

Loading ...
Support Center